Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.53

+4.5%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: jayhawk969 who wrote (8213)	4/30/2003 10:07:23 PM
From: Michael Young	Read Replies (1) of 52153

DOVP is very interesting. Since the IPO fiasco it has just floundered on no volume. They have quite a bit of cash, and several products in late stage trials. Bicafidine for dental pain is in Phase III. Ocinaplon will be entering Phase III soon for anxiety. Both products are on a path for approval in 2006. They burned $12 million in 2002. That should increase somewhat in the next few years. I keep passing on the stock because it shows no "energy." But I have a fear that I will stay away, only to see it trading around $15 in a year. MIKE

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next